E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019744 |
E.1.2 | Term | Hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10008912 |
E.1.2 | Term | Chronic hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To evaluate the efficacy of ledipasvir/sofosbuvir (LDV/SOF) in treating HCV infection in pediatric subjects who are undergoing cancer chemotherapy, as measured by the proportion who achieve a sustained virologic response 12 weeks after the end of HCV treatment (SVR12)
- To evaluate the safety and tolerability of treatment with LDV/SOF for 12 weeks |
|
E.2.2 | Secondary objectives of the trial |
- To determine the proportion of subjects who attain SVR at 4 and 24 weeks after cessation of HCV treatment (SVR4 and SVR24)
- To evaluate the kinetics of circulating HCV RNA during treatment and after cessation of HCV treatment |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Parent or legal guardian must be able to provide written informed consent prior to any screening evaluations and willing to comply with study requirements. A subject will provide assent if possible; written assent will be provided if the subject has the ability to read and write, as determined by the Ethics Committee and the Investigator’s assessment. 2) Male or female, 12 to <18 years of age (consent of parent or legal guardian required) 3) Weight ≥ 35 kg 4) Chronic HCV infection (≥ 6 months) documented by medical history or, if available, liver biopsy 5) HCV genotype 1 or 4 at screening 6) Receiving a protocol-approved maintenance chemotherapy regimen for a hematological malignancy (see Section 5.3.1) 7) HCV RNA ≥ 1000 IU/mL at screening 8) Adequate hematologic function (absolute neutrophil count >=500/mm3, hemoglobin >=10 g/dL) 9) Treatment naïve or experienced, where treatment-experienced is defined as prior treatment failure or intolerance to a regimen including interferon with or without ribavirin that was completed at least 8 weeks prior to Baseline/Day 1 10) Females of childbearing potential (as defined in Appendix 4) must have a negative pregnancy test at Screening and Baseline/Day 1. 11) Subject able to provide written assent, if they have the ability to read and write, as determined by IRB/IEC/local requirements and Investigator’s discretion
|
|
E.4 | Principal exclusion criteria |
1) Co-infection with HIV, acute hepatitis A virus (HAV) infection or chronic HBV coinfection (HBsAg positive [HBsAg+] at screening) 2) Decompensated liver disease defined as INR > 1.2 x ULN, platelets < 50,000/mm3, serum albumin < 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage) 3) Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of orally administered medications 4) Chronic liver disease of non-HCV etiology (eg, hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency) 5) Evidence of hepatocellular carcinoma (HCC) or other non-hematologic malignancy (with the exception of certain resolved skin cancers) 6) History of solid organ or bone marrow transplantation 7) Active or recent history (≤ 1 year) of alcohol or drug abuse 8) Serum creatinine > 1.5 mg/dL 9) Estimated glomerular filtration rate < 90 mL/min/1.73m2, as calculated by the Schwartz formula 10) Investigational agents taken within the past 28 days (except with the prior written approval of the Sponsor) 11) Use of any prohibited concomitant medications as described in Section 5.3 12) Pregnant or lactating subjects 13) Sexually-active males or females of childbearing potential who are not willing to use an effective method of contraception during the study (see Appendix 4 for further details) 14) Unable to swallow the LDV/SOF FDC 90mg/400mg and the LDV/SOF FDC 22.5mg/100mg placebo tablets 15) Known hypersensitivity to LDV, SOF, metabolites, or formulation excipients 16) Subject unable to comply with the dosing instructions for study drug administration and/or unable to complete the study schedule of assessments |
|
E.5 End points |
E.5.1 | Primary end point(s) |
SVR12 in all enrolled and treated subjects. No hypothesis testing will be performed. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 weeks after completion of treatment. |
|
E.5.2 | Secondary end point(s) |
- SVR4 and SVR24 - HCV viral kinetics HCV RNA change from Baseline/Day 1 The proportion of subjects with virologic failure |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
4 weeks and 24 weeks following completion of treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 5 |